ZyVersa Therapeutics, Inc. (ZVSA)
NASDAQ: ZVSA · Real-Time Price · USD
1.150
-0.080 (-6.50%)
At close: Nov 20, 2024, 4:00 PM
1.140
-0.010 (-0.87%)
Pre-market: Nov 21, 2024, 7:30 AM EST
ZyVersa Therapeutics Employees
ZyVersa Therapeutics had 7 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$4,182,635
Market Cap
1.24M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7 | 0 | - |
| Dec 31, 2022 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| China SXT Pharmaceuticals | 75 |
| Tenon Medical | 21 |
| TFF Pharmaceuticals | 19 |
| Catheter Precision | 14 |
| Altamira Therapeutics | 10 |
| Bluejay Diagnostics | 10 |
| Entero Therapeutics | 9 |
| Revelation Biosciences | 9 |
ZVSA News
- 1 day ago - ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial - GlobeNewsWire
- 7 days ago - ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 16 days ago - ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes - GlobeNewsWire
- 23 days ago - ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs - GlobeNewsWire
- 4 weeks ago - ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases - GlobeNewsWire
- 5 weeks ago - ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months - GlobeNewsWire
- 5 weeks ago - ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors - GlobeNewsWire
- 6 weeks ago - ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications - GlobeNewsWire